Landos Biopharma to Host Corporate Update Call

Rhea-AI Summary

Landos Biopharma Inc. (NASDAQ: LABP) will announce its third quarter 2021 financial results on November 15, 2021. Following the announcement, the company will host a live webcast at 8:00 am ET for a corporate update, accessible via its investor relations website or through phone dial-in options.

Landos Biopharma focuses on developing innovative oral therapeutics for autoimmune diseases using its LANCE® Advanced A.I. platform. Its lead candidates include omilancor for ulcerative colitis and NX-13, aimed at the same condition, along with LABP-104 targeting systemic lupus erythematosus.

BLACKSBURG, Va., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma Inc. (NASDAQ: LABP) today announced that it will report third quarter 2021 financial results and host a conference call to provide a corporate update on November 15, 2021.

Following the release of the financial results, Landos will host a live webcast at 8:00 am ET. The webcast can be accessed through the Company’s investor relations website at https://ir.landosbiopharma.com/, or by dialing 1-877-317-6789 (Toll Free) or 1-412-317-6789 (International) and asking to join the Landos Corporate Update call. The webcast will be archived and be available for replay on the Company’s investor relations website.

About Landos Biopharma
Landos Biopharma is a clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to discover and develop novel oral therapeutics for patients with autoimmune diseases. Using the LANCE® platform, the Company discovers new mechanisms of action, including the LANCL2, NLRX1 and PLXDC2 immunometabolic pathways at the interface of immunity and metabolism. Landos’ lead product candidate, omilancor targets the LANCL2 pathway and is a novel oral, gut-restricted, small molecule first-in-class therapeutic in development for the treatment of ulcerative colitis and Crohn’s disease. Landos’ second product candidate, NX-13, targets the NLRX1 pathway and is a novel, oral, gut-restricted small molecule first-in-class therapeutic in development for the treatment of ulcerative colitis. Landos discovered and is also developing LABP-104, a novel, oral small molecule first-in-class therapeutic targeting the LANCL2 pathway for the treatment of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).

For more information, please visit www.landosbiopharma.com.

Contact

Andi Rose / Tanner Kaufman / Kara Sperry
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449

FAQ

When will Landos Biopharma report its financial results for Q3 2021?

Landos Biopharma will report its Q3 2021 financial results on November 15, 2021.

What time is the live webcast for Landos Biopharma's corporate update?

The live webcast for Landos Biopharma's corporate update will begin at 8:00 am ET on November 15, 2021.

How can I access the webcast for Landos Biopharma's Q3 results?

You can access the webcast through Landos Biopharma's investor relations website or by dialing the provided phone numbers.

What is the lead product candidate of Landos Biopharma?

Landos Biopharma's lead product candidate is omilancor, which targets the LANCL2 pathway for ulcerative colitis treatment.

What other product candidates are being developed by Landos Biopharma?

Landos Biopharma is also developing NX-13 for ulcerative colitis and LABP-104 for systemic lupus erythematosus and rheumatoid arthritis.